Previous 10 | Next 10 |
– Now Enrolling Patients in Two Registration-Directed Trials for Lead Candidate, Oral Fadraciclib – – Expecting Key Data Readouts for Oral Fadraciclib in 2022 – – Planning to Launch Two Registration-Directed Studies for Diffe...
BERKELEY HEIGHTS, N.J., Dec. 23, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that the Company will participate in...
Cyclacel Pharmaceuticals, Inc. (CYCC) Q3 2021 Earnings Conference Call November 10, 2021 4:30 PM ET Company Participants Spiro Rombotis - President and Chief Executive Officer Paul McBarron - Executive Vice President, Finance and Chief Operating Officer Mark Kirschbaum - Senior Vice President...
Cyclacel Pharmaceuticals (NASDAQ:CYCC): Q3 GAAP EPS of -$0.47 beats by $0.23. Press Release As of September 30, 2021, cash and cash equivalents totaled $40.2M, compared to $43.6M as of June 30, 2021. For further details see: Cyclacel Pharmaceuticals EPS beats by $0.23
- Second Phase 1/2 Study of Fadraciclib Now Enrolling Patients in Leukemia - - Cash Runway to Early 2023 - - Conference Call Scheduled November 10, 2021 at 4:30 p.m. ET - BERKELEY HEIGHTS, N.J., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc....
OTCQX:ACRGF, ADMA, AEVA, DADAAMPE, AMWL, APP, APPH, ASND, ATO, OTCPK:ATUSF, AZUL, BANX, BARK, BIOL, BKEP, BMBL, BOXL, BRFS, BRKS, BROS, BSQR, BW, BYND, BZH, CBAY, CCCS, CCMP, CGRN, CLSD, CLVR, CRCT, CYCC, DARE, DGII, DIS, EDRY, EGLX, ELMS, ENS, EVOK, FICO, FIGS, FOSL, FSM, GAU, GDRX, GEVO, OT...
Cyclacel Pharmaceuticals (NASDAQ:CYCC) announces the dosing of the first patient in the company’s multi-cohort Phase 1/2 study of oral fadraciclib in patients with leukemias or myelodysplastic syndromes (MDS). The Phase 1/2 registration-directed trial, designated CYC065-102, uses a str...
BERKELEY HEIGHTS, N.J., Nov. 05, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced dosing of the first patient in the Company...
BERKELEY HEIGHTS, N.J., Oct. 29, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce third quarter financial results a...
Cyclacel is a biotech company developing small molecule drugs for treating cancer and other diseases. CEO Spiro Rombotis joined us for a discussion about cancer resistance and clinical trials. Investor updates including recent study of oral Fadraciclib in patients with advanced tu...
News, Short Squeeze, Breakout and More Instantly...
Cyclacel Pharmaceuticals Inc. Company Name:
CYCC Stock Symbol:
NASDAQ Market:
Cyclacel Pharmaceuticals Inc. Website:
BERKELEY HEIGHTS, N.J., June 26, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced the receipt of a notice from the European ...
- Novel CDK2/9 inhibitor fadraciclib induces anaphase catastrophe, a novel cancer-specific mechanism of action - BERKELEY HEIGHTS, N.J., June 04, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”...
- Clinical, PK and PD data from novel CDK2/9 inhibitor fadraciclib monotherapy studies support ongoing proof of concept study in patients with solid tumors and lymphoma - BERKELEY HEIGHTS, N.J., June 03, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP;...